Literature DB >> 23463097

Oestrogen receptors are prognostic factors in malignant peritoneal mesothelioma.

Krishna Pillai1, Mohammad Hossein Pourgholami, Terence C Chua, David Lawson Morris.   

Abstract

BACKGROUND: Malignant peritoneal mesothelioma (MPM) is a rare and fatal cancer. Females are found to survive longer than males after treatment, suggesting a possible involvement of hormonal factors. Estradiol is involved in cellular proliferation of a number of cancers and acts mainly through oestrogen receptors (ERs). Hence, we examined the expression of oestrogen receptors with correlation to prognosis.
METHODS: Oestrogen receptors expression was examined using immunohistochemistry on 42 paraffin-embedded sections of MPM tumours. Kaplan-Meier survival curves were analysed to determine the significance of ER expression in relation to prognosis.
RESULTS: ER-β (nuclear) was detected in 33 (79 %) patients. ER-β was also detected in the cellular cytoplasm of 9 (21 %) patients. Presence of ER-β (nuclear) was associated with favourable survival (univariate analysis, P = 0.001), whereas the presence of ER-β (cytoplasm) was associated with a poor survival (P = 0.014). Multivariate Cox regression analysis revealed the absence of ER-β (nuclear) and the presence of ER-β (cytoplasm) to be independent predictive factors for poor disease outcome (hazard ratio 5.4, 95 % confidence interval 1.86-15.75; P = 0.002 and hazard ratio 8.0, 95 % confidence interval 1.8-34; P = 0.005), respectively. ER-α (nuclear) was detected in only 4 (9 %) of patients and not statistically significant (univariate analysis, P = 0.066).
CONCLUSION: The presence of ER-β (cytoplasm) is associated with poor prognosis. The favourable survival association observed in patients with ER-β (nuclear) raises a question about the molecular mechanisms of the tumorigenic roles of ER-β in each cellular compartment and requires further studies.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23463097     DOI: 10.1007/s00432-013-1408-2

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  36 in total

Review 1.  Comprehensive management of peritoneal surface malignancy using cytoreductive surgery and perioperative intraperitoneal chemotherapy: the Washington Cancer Institute approach.

Authors:  Paul H Sugarbaker
Journal:  Expert Opin Pharmacother       Date:  2009-08       Impact factor: 3.889

2.  Sex difference in diffuse malignant peritoneal mesothelioma.

Authors:  T D Yan; E Popa; E A Brun; C A Cerruto; P H Sugarbaker
Journal:  Br J Surg       Date:  2006-12       Impact factor: 6.939

3.  Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer.

Authors:  J M Harvey; G M Clark; C K Osborne; D C Allred
Journal:  J Clin Oncol       Date:  1999-05       Impact factor: 44.544

Review 4.  Epidemiology of peritoneal mesothelioma: a review.

Authors:  P Boffetta
Journal:  Ann Oncol       Date:  2006-10-09       Impact factor: 32.976

5.  Impact of age at diagnosis on prostate cancer treatment and survival.

Authors:  Seth K Bechis; Peter R Carroll; Matthew R Cooperberg
Journal:  J Clin Oncol       Date:  2010-12-06       Impact factor: 44.544

6.  Putative functional characteristics of human estrogen receptor-beta isoforms.

Authors:  B Peng; B Lu; E Leygue; L C Murphy
Journal:  J Mol Endocrinol       Date:  2003-02       Impact factor: 5.098

7.  Intratumoral estrogens and estrogen receptors in human non-small cell lung carcinoma.

Authors:  Hiromichi Niikawa; Takashi Suzuki; Yasuhiro Miki; Satoshi Suzuki; Shuji Nagasaki; Junichi Akahira; Seijiro Honma; Dean B Evans; Shin-Ichi Hayashi; Takashi Kondo; Hironobu Sasano
Journal:  Clin Cancer Res       Date:  2008-06-25       Impact factor: 12.531

8.  Malignant peritoneal mesothelioma: a multicenter study on 81 cases.

Authors:  V de Pangher Manzini; L Recchia; M Cafferata; C Porta; S Siena; L Giannetta; F Morelli; F Oniga; A Bearz; V Torri; M Cinquini
Journal:  Ann Oncol       Date:  2009-07-27       Impact factor: 32.976

Review 9.  The expression and function of estrogen receptor alpha and beta in human breast cancer and its clinical application.

Authors:  S-I Hayashi; H Eguchi; K Tanimoto; T Yoshida; Y Omoto; A Inoue; N Yoshida; Y Yamaguchi
Journal:  Endocr Relat Cancer       Date:  2003-06       Impact factor: 5.678

10.  Clinical presentation of peritoneal mesothelioma.

Authors:  Yair I Z Acherman; Laura S Welch; Christina M Bromley; Paul H Sugarbaker
Journal:  Tumori       Date:  2003 May-Jun
View more
  10 in total

1.  Malignant pericardial mesothelioma : A systematic review of current practice.

Authors:  S Cao; S Jin; J Cao; J Shen; H Zhang; Q Meng; B Pan; Y Yu
Journal:  Herz       Date:  2017-01-27       Impact factor: 1.443

Review 2.  Advances in malignant peritoneal mesothelioma.

Authors:  Shoubo Cao; Shi Jin; Jingyan Cao; Jing Shen; Jing Hu; Dehai Che; Bo Pan; Jiawen Zhang; Xiaoxi He; Dian Ding; Feifei Gu; Yan Yu
Journal:  Int J Colorectal Dis       Date:  2014-10-21       Impact factor: 2.571

Review 3.  Advances in the management of peritoneal mesothelioma.

Authors:  Ali Raza; Wei-Ching Huang; Kazuaki Takabe
Journal:  World J Gastroenterol       Date:  2014-09-07       Impact factor: 5.742

4.  Effects of sex hormones on survival of peritoneal mesothelioma.

Authors:  Yeqian Huang; Nayef A Alzahrani; Winston Liauw; David L Morris
Journal:  World J Surg Oncol       Date:  2015-06-26       Impact factor: 2.754

5.  Agonist activation of estrogen receptor beta (ERβ) sensitizes malignant pleural mesothelioma cells to cisplatin cytotoxicity.

Authors:  Giulia Pinton; Arcangela G Manente; Antonio Daga; Michele Cilli; Maurizio Rinaldi; Stefan Nilsson; Laura Moro
Journal:  Mol Cancer       Date:  2014-10-02       Impact factor: 27.401

6.  Analysis of prognostic factors of patients with malignant peritoneal mesothelioma.

Authors:  Wenjie Yin; Guoqi Zheng; Kunna Yang; Hui Song; Yufei Liang
Journal:  World J Surg Oncol       Date:  2018-03-05       Impact factor: 2.754

7.  Exemestane blocks mesothelioma growth through downregulation of cAMP, pCREB and CD44 implicating new treatment option in patients affected by this disease.

Authors:  Barbara Nuvoli; Sabrina Germoni; Carlotta Morosetti; Raffaela Santoro; Giancarlo Cortese; Serena Masi; Iole Cordone; Rossella Galati
Journal:  Mol Cancer       Date:  2014-03-21       Impact factor: 27.401

8.  Stimulatory actions of IGF-I are mediated by IGF-IR cross-talk with GPER and DDR1 in mesothelioma and lung cancer cells.

Authors:  Silvia Avino; Paola De Marco; Francesca Cirillo; Maria Francesca Santolla; Ernestina Marianna De Francesco; Maria Grazia Perri; Damiano Rigiracciolo; Vincenza Dolce; Antonino Belfiore; Marcello Maggiolini; Rosamaria Lappano; Adele Vivacqua
Journal:  Oncotarget       Date:  2016-08-16

Review 9.  Malignant peritoneal mesothelioma: clinical aspects, and therapeutic perspectives.

Authors:  Stergios Boussios; Michele Moschetta; Afroditi Karathanasi; Alexandros K Tsiouris; Foivos S Kanellos; Konstantina Tatsi; Konstantinos H Katsanos; Dimitrios K Christodoulou
Journal:  Ann Gastroenterol       Date:  2018-09-14

10.  Level of mesothelin expression can indicate the prognosis of malignant pleural mesothelioma.

Authors:  Feifei Feng; Huanan Zhang; Ying Zhang; Hui Wang
Journal:  Transl Cancer Res       Date:  2020-12       Impact factor: 1.241

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.